Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days – ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels following 28 days of once-daily dosing – – Data support further development of ARV-102 in additional

#ARVN Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

www.stocktitan.net/news/ARVN/arvinas-announ...

Trip to Denver for supplies - there was a #Thriftscore! @arcthrift #WhatAreYouReading #BookReviews #20thCenturyHistory #MilitaryHistory #VietnameseHistory #VietnamWar #SouthVietnameseHistory #AmericanHistory #NorthVietnameseHistory #ColdWar #Communism #Insurgency #SpecialForces #ARVN #HistBookChat

Yowza! - the Mailman delivered!! Gotta get reading right away! #WhatAreYouReading #BookReviews #20thCenturyHistory #MilitaryHistory #VietnameseHistory #AmericanHistory #VietNamWar #ColdWar #SouthVietnam #NorthVietnam #USMC #ICorps #VietCong #Insurgency #NVA #ARVN #COIN #SoutheastAsia #HistBookChat

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ACM 596.2x
2. #ARVN 191.0x
3. #ATLX 44.4x
4. #SNCY 40.0x
5. #TOI 39.8x

#OptionFlow #OptionsTrading #Trading

#ARVN Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ARVN/arvinas-report...

FDA Reviews Groundbreaking Breast Cancer Drug: First PROTAC Therapy Shows Superior Trial Results Novel PROTAC drug vepdegestrant demonstrates improved survival in ESR1-mutated breast cancer patients. Phase 3 results published in NEJM. See trial data.

#ARVN Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

www.stocktitan.net/news/ARVN/arvinas-announ...

Breakthrough: Arvinas Files Historic First PROTAC Cancer Drug Application, Advances Novel Pipeline First PROTAC degrader enters FDA review for breast cancer treatment. See Q2 updates on groundbreaking protein degradation pipeline and $861M cash position.

#ARVN Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ARVN/arvinas-report...

Martin Koenigsberg's review of Tim Page's Nam 4/5: When I found this book at a Thrift store/Charity Shop - I will admit I picked it up for the clear and strong photography, the good condition and the price. When I got it home and had a further lo...

Just finished my 53rd Book Review of the Year!! #WhatAreYouReading #BookReviews #20thCenturyHistory #MilitaryHistory #VietnameseHistory #AmericanHistory #SouthVietnameseHistory #ColdWar #Communism #SEATO #ARVN #VC #VietnamWar #WargameResearch #HistoryBookChat
www.goodreads.com/review/show/...

Pioneering Biotech CEO Steps Down: How Arvinas' Houston Transformed Protein Degradation Drug Development After 8 years of breakthrough PROTAC developments, CEO transitions to Board Chair role. Learn how this strategic succession maintains Arvinas' momentum in protein degradation. See details.

#ARVN Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

www.stocktitan.net/news/ARVN/arvinas-announ...

Trip to Denver for Supplies - There was a #ThriftScore!! @arcthrift #WhatAreYouReading #BookReviews #20thCenturyHistory #MilitaryHistory #VietnameseHistory #AmericanHistory #ColdWar #Communism #SEATO #ARVN #VC #SouthVietnameseHistory #VietnamWar #WargameResearch #HistoryBookChat

On June 10, 2025, Logos Global Management (6.4%) called for a strategic reset of #ARVN ARVINAS, INC., urging a shareholder distribution, reduced spending, suspension of early-stage pipeline investments, and pursuit of a strategic partner for the lead asset.

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress Arvinas (NASDAQ: ARVN) presented promising preclinical data for ARV-393, their PROTAC BCL6 degrader, at EHA 2025. The drug showed significant single-agent activity in models of lymphoma, particularly in nodal T-follicular helper cell lymphoma (AITL) and transformed follicular lymphoma. When combined with small molecule inhibitors, ARV-393 demonstrated enhanced tumor growth inhibition and tumor regressions in aggressive DLBCL models. Key findings include ≥95% tumor growth inhibition in tFL models and successful combinations with drugs like tazemetostat and venetoclax. RNA sequencing revealed ARV-393's mechanism inhibits tumor cell cycle progression and promotes differentiation. A Phase 1 study is currently enrolling patients with relapsed/refractory non-Hodgkin lymphoma.

#ARVN Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

www.stocktitan.net/news/ARVN/arvinas-presen...

First-Ever PROTAC Cancer Drug Heads to FDA: Arvinas' Breakthrough Breast Cancer Treatment Breakthrough PROTAC therapy for ESR1-mutated breast cancer seeks FDA approval after successful Phase 3 trial. See ASCO presentation and NEJM data.

#ARVN Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

www.stocktitan.net/news/ARVN/arvinas-announ...

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer Arvinas and Pfizer announced significant Phase 3 VERITAC-2 trial results for vepdegestrant, their novel PROTAC drug for advanced breast cancer. The drug showed a 2.9-month improvement in median progression-free survival compared to fulvestrant in ESR1-mutant, ER+/HER2- breast cancer patients, reducing disease progression risk by 43%. Vepdegestrant demonstrated strong efficacy with a median PFS of 5.0 months versus 2.1 months for fulvestrant in ESR1-mutant patients. The drug was well-tolerated with low rates of gastrointestinal side effects and few discontinuations. As the first PROTAC evaluated in Phase 3 trials showing benefit in breast cancer patients, Arvinas and Pfizer plan to submit an NDA to the FDA in H2 2025. The trial results were presented at ASCO and published in the New England Journal of Medicine.

#ARVN Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

www.stocktitan.net/news/ARVN/arvinas-and-pf...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BIDU, #SNY, #ARVN, #REAL, #CLSK

#OptionFlow #OptionsTrading #Trading

Pomerantz Law Firm Probes Investor Claims Against Arvinas, Inc. Due to Recent Developments The Pomerantz Law Firm is probing potential securities fraud concerning Arvinas, Inc., following significant news that impacted the company’s stock.

Pomerantz Law Firm Probes Investor Claims Against Arvinas, Inc. Due to Recent Developments #United_States #New_York #Pomerantz_LLP #Arvinas_Inc #ARVN

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ARVN, #TTWO, #VG, #WFC, #BWA

#OptionFlow #OptionsTrading #Trading

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#MSFT, #CRWV, #TEM, #ARVN, #VG

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ARVN 29.9x
2. #STNG 18.0x
3. #JBLU 13.9x
4. #TTWO 10.6x
5. #SMR 8.8x

#OptionFlow #OptionsTrading #Trading

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu May 1st - #CORZ #ARVN #MPW #AG #NAOV #CLSK #NGD #JBLU #ZCAR #WULF #RIG #BBAI #WOLF #VRSSF #PTEN #RGTI #QBTS #OKLO #CEP #CDE - More: crystalequityresearch.com/SmCpStr/ - #smallcap

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CGNT, #NXE, #TTEK, #IR, #ARVN

#OptionFlow #OptionsTrading #Trading

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update Arvinas (ARVN) reported Q1 2025 financial results and significant corporate updates. The company announced positive Phase 3 VERITAC-2 trial results for vepdegestrant in breast cancer, supporting upcoming regulatory filings. However, Arvinas and Pfizer removed two planned Phase 3 combination trials from their development plan. The company presented promising first-in-human data for ARV-102 in neuroscience, showing effective blood-brain barrier penetration. Financially, Arvinas reported $954.3 million in cash and $188.8 million in revenue for Q1 2025. The company announced a significant restructuring, including a workforce reduction of approximately one-third, to extend cash runway into H2 2028. R&D expenses were $90.8 million, up from $84.3 million year-over-year, while G&A expenses increased to $26.6 million from $24.3 million.

#ARVN Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/ARVN/arvinas-report...

First Pivotal Data for Revolutionary Breast Cancer Drug to be Unveiled at ASCO 2025 Late-Breaking Session First-in-class PROTAC breast cancer therapy data to be revealed at prestigious ASCO conference. Partnership with Pfizer shows promising advancement. Get insights.

#ARVN Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

www.stocktitan.net/news/ARVN/arvinas-announ...

Game-Changing Parkinson's Drug Shows 90% Target Reduction in First Human Trial Novel PROTAC drug achieves unprecedented brain barrier penetration with 90% LRRK2 reduction. Phase 1 Parkinson's trial now underway. Full analysis inside.

#ARVN Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

www.stocktitan.net/news/ARVN/arvinas-presen...

Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease First-in-human trial reveals safety and efficacy data for ARV-102, a novel PROTAC degrader targeting LRRK2 protein in Parkinson's disease. Full analysis inside.

#ARVN Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases

www.stocktitan.net/news/ARVN/arvinas-announ...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Mar 11th - #FUBO #CORZ #AG #HSAI #JBLU #HL #WULF #TSVT #IQ #VRN #RGTI #SNOA #VKTX #QBTS #NNOX #LUNR #LPG #FRO #CDE #ARVN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Tue Mar 11th - #TBRG #ULCC #VINP #AAT #BARK #CUI #DQ #ELME #JBGS #LANV #PARR #REX #SOL #VATE #SATL #RMBL #PAYS #OSBC #MBOT #HTLD #FFAI #CRNC #ARVN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial Arvinas (ARVN) and Pfizer (PFE) announced positive topline results from their Phase 3 VERITAC-2 clinical trial for vepdegestrant, a first-in-class investigational oral PROTAC ER degrader for breast cancer treatment.The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, showing statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population, though the trial did not reach statistical significance in the intent-to-treat population.Vepdegestrant was generally well tolerated, with a safety profile consistent with previous studies. Overall survival data was not mature at analysis time, with less than 25% of required events occurred. The FDA granted Fast Track designation for vepdegestrant in February 2024 for monotherapy in ER+/HER2- advanced or metastatic breast cancer patients previously treated with endocrine-based therapy.

#ARVN Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

www.stocktitan.net/news/ARVN/arvinas-and-pf...